[Fulvestrant in heavily pretreated postmenopausal women with advanced breast cancer]. / Tratamiento con fulvestrant en mujeres posmenopáusicas con cáncer de mama avanzado tras tratamiento hormonal previo.
Med Clin (Barc)
; 133(10): 371-4, 2009 Sep 19.
Article
en Es
| MEDLINE
| ID: mdl-19339025
ABSTRACT
BACKGROUND AND OBJECTIVE:
Fulvestrant (Flv) is a pure antiestrogen without agonist activity. Flv is effective as second line treatment in postmenopausal women with advanced breast cancer after tamoxifen. MATERIAL ANDMETHOD:
We performed a retrospective study of 36 consecutive postmenopausal women treated with Flv and advanced breast cancer progressing on prior therapies. 62,8% received Flv as third line treatment or more (all patients had previously received endocrine treatment for early or advanced breast cancer), 54,3% adjuvant chemotherapy and 67,5% received chemotherapy for metastatic disease. Our objective was to analyze the response rate, clinical benefit, time to progression (TTP) and toxicity profile.RESULTS:
In our study 11,4% patients had partial responses (PR) and 22,9% had a stable disease (SD) >24 weeks. Clinical benefit rate (CB) [RP+RC+SD] 31,4%. TTP 4,2 months (CI 95%, 2,6-5,8), with a median follow-up of 8,9 months. Flv was well tolerated, 22,9% patients had adverse events, all grade I/II, and only 5,7% of women gave up the treatment.CONCLUSIONS:
These data demonstrate that Flv is an effective and safe therapy for heavily pre-treated postmenopausal women with advanced breast cancer.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Carcinoma Lobular
/
Carcinoma Ductal de Mama
/
Antineoplásicos Hormonales
/
Estradiol
/
Antagonistas de Estrógenos
Tipo de estudio:
Evaluation_studies
/
Observational_studies
/
Prognostic_studies
Límite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Middle aged
Idioma:
Es
Revista:
Med Clin (Barc)
Año:
2009
Tipo del documento:
Article